# Healthcare Podcast Weekly Digest: May 8–15, 2026

> Healthcare podcast synthesis for May 8–15, 2026. FDA Commissioner Makary resigns, Eli Lilly's blowout Q1 lifts the GLP-1 bull case, and the biotech rotation toward developmental-stage names accelerates.


## Healthcare Podcast Weekly Digest

### Week of May 8 – May 15, 2026

```request-access
variant: ghost
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## Opening Summary

Healthcare was dominated this week by two seismic events: the resignation of FDA Commissioner **Marty Makary** on May 12 over the administration's fruit-flavored e-cigarette authorization, and **Eli Lilly's** blowout Q1 print that produced a $2B guide raise and a fresh round of Lebanon, Indiana capex commitments. Beneath the headlines, the sector remains bifurcated: **XBI is up ~70% on a one-year trailing basis** with biotech sentiment turning "cautiously optimistic," while **XLV trails the S&P 500 YTD** and managed care continues to grind through elevated Medicare Advantage utilization. Capital-markets activity is record-setting: ~$3.2B raised across 10 biotech IPOs YTD, a record Q1 in biotech secondaries, and a chunky deal tape (UCB/Candid $2B upfront, Angelini/Catalyst $4.1B, Bayer/Perfused ~$300M upfront).

Below is the synthesis.

---

## Key People This Week

| Speaker | Affiliation | Key Quote / Position |
| --- | --- | --- |
| Sam Fazeli | Pharma/biotech analyst | "Injectable obesity drugs are flying off the shelves ex-US"; LLY "feathering the nest" for post-GLP-1 LOE via ~$14.5B of M&A YTD. (Biotech Hangout, May 8) |
| Dr. Scott Gottlieb | Former FDA Commissioner; UNH/PFE/Illumina board | On Makary: "I don't think people would have put that into the press multiple outlets unless they had some substantiation." Cold water on Hantavirus vaccine trade. (Squawk Pod, May 11) |
| Peter Mantas | GP & CIO, Logos LP | Makary removal "quite bullish for gene therapy companies, cell therapy companies, gene editing companies"; expects "the biggest biotech bubble that we've ever seen." (Intelligent Investing, May 13) |
| Frank Watanabe | CEO, Arcutis; Vice Chair, BIO Board | MFN "will very quickly destroy the biopharmaceutical industry in the United States if it's implemented." (Citeline, May 12) |
| Paul Matteis | Sell-side biotech analyst | "2025 was the commercial biotech year... this year, a number of those names have been laggards and it feels like it's been the year of developmental stage biotech." (Biotech Hangout, May 8) |
| Judith Feingold | Equity Analyst, Pharma & Biotech, Capital Group | GLP-1s are "almost a consumer market at this point"; conviction in small/mid-cap biotech where "the science and innovation is very, very rich." (Capital Ideas, May 14) |
| Albert Bourla | CEO, Pfizer | "We never say never... but right now... it is time to execute on the AI transformation of this organisation, and that requires not the disruption of mega-mergers." (Citeline, May 11) |
| Mike Dustar | CEO, Novo Nordisk | "~80% of Wegovy pill users are GLP-1 treatment-naive patients... we see limited cannibalization from our own injectable Wegovy." (Citeline, May 11) |
| Graig Suvannavejh | Sell-side analyst | "April 2026 was the worst month relative month for healthcare versus the S&P 500 since 2009"; calls 2026 "a very good year for biotech." (Biotech Hangout, May 8) |
| Tim Noel | CEO, UnitedHealthcare | "Prior authorization is an essential safeguard but should only be used when it truly protects patients and improves care"; UHC cutting an additional 30% of PA requirements. |

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## Hot Topics

### Eli Lilly (LLY) – the dominant single name of the week

- Q1 print beat consensus; full-year revenue guide raised by $2B to ~$82B low end; web sources cite a wider $82–85B band and $35.50–$37.00 adj EPS, driven by ~$12.8B of combined Mounjaro + Zepbound. Stock was up ~9–10% the day prior to recording on May 8 and another ~3–5% intraday.
- **Kisunla** (Alzheimer's) Q1 revenue $124M vs. $76M consensus; subcutaneous formulation cited as the uptake driver.
- **Foundayo** (oral orforglipron) launched ~April 9; "less impressive start than Novo's product" early but not the FY revenue swing factor.
- **ATTAIN-MAINTAIN / SURMOUNT-MAINTAIN** at ECO (May 12): patients stepping down from injectables to Foundayo or low-dose Zepbound maintained essentially all prior weight loss out to week 52/112.
- Capacity: another $4.5B committed to Lebanon, IN sites on May 6; total Indiana capex >$21B since 2020, including a new dedicated genetic medicine manufacturing facility.
- Sell-side: Guggenheim raised PT to $1,235 from $1,183 (Buy) on May 8.
- LLY employer-direct channel "is disenfranchising the PBMs to a degree" (Fazeli).

### UnitedHealth (UNH)

- Eliminating prior authorization on an additional 30% of services by year-end 2026; PA currently required on only 2% of medical services, ~92% approved, average <24 hours.
- Optum Rx launching a "transparent" fee-based PBM model decoupled from list price and Rx volume.
- BofA's Kevin Fischbeck raised PT to $420 from $380 (Neutral) on May 13, with a "bullish" tone at the BofA Healthcare Conference; management confident in getting back to at least the low end of target margins in most businesses by 2028.
- Web context: UNH reportedly shed ~1.3M MA members (~8%) to protect margin; Q1 MLR ~85.3% beat the ~85.5% consensus; EPS $7.23; final 2027 MA rate notice delivered a 2.48% increase vs. the 0.09% original proposal; Morgan Stanley reportedly moved to Top Pick.

### Novo Nordisk (NVO)

- Oral Wegovy launched in the US Jan 5, 2026, described as "the strongest ever GLP-1 volume launch in the US" with ~1.3M Q1 prescriptions and ~$354M of revenue (inflated by pipeline fill).
- ~50% of oral Wegovy scripts are through Novocare/self-pay at $149/month, roughly 1/10th the prior-year injectable price; ASP/margin compression is the swing factor.
- ~10,000 headcount reductions over the trailing 12 months; H2 2026 first international oral Wegovy launches expected.
- Scrip analysts saw "no clear signs of [NVO] regaining overall market leadership in obesity from Lilly."

### Pfizer (PFE)

- Vyndamax patent settlement delays generic entry from 2029 to 2031; Q1 Vyndamax $1.6B (+8% YoY); CEO Bourla guides to "a five-year period of high single-digit CAGR starting in 2029."
- ~$7B BD capacity per CFO Denton; explicit "no" to mega-mergers near-term in favor of AI transformation. LOEs: Imbruvica 2027, Eliquis 2028.

### J&J (JNJ)

- Discontinuing two LBCL CAR-T programs (Prislo-cel and JNJ-9530) for portfolio reasons, not efficacy. Carvykti remains the focus; 2025 sales $1.89B (+96% YoY).
- DUET IBD combo (guselkumab + fezakinumab) missed primary endpoint; Schimmer publicly criticized JNJ for "painting it in a brighter light than it should be."

### AbbVie (ABBV) / Merck (MRK) / BMY

- **ABBV:** RINVOQ patent settled out to 2037; Skyrizi + RINVOQ portfolio "doing magically."
- **MRK:** Fazeli says Keytruda US exclusivity may extend "till 2033" via formulation/method patents. Summit's Harmony-3 (ivonescimab) did NOT meet PFS interim threshold, a mild positive read for Keytruda; Harmony-6 OS late-breaker at ASCO is the key tell.
- **BMY:** Breyanzi Q1 $411M (+56%), taking CAR-T share from Gilead.

### Biotech Standouts

- **Revolution Medicines (RVMD):** Phase 3 Diraxon (pan-RAS) in 2L pancreatic OS 13.2 vs. 6.7 months; raised $2.2B (upsized from $1B); pan-RAS pancreatic market sized at "$8 to $10 billion" (Fazeli). VC chatter has Merck evaluating a $30B take-out.
- **Cytokinetics (CYTK):** ACACIA aficamten in non-obstructive HCM; stock "well over 100% off the bottom."
- **Moderna (MRNA):** +12% Fri / +5% Mon on Hantavirus headlines; Evercore notes "no meaningful revenue opportunities from the Hantavirus and basically just trades on outbreak headlines."
- **uniQure (QURE):** AMT-130 in Huntington's, "75% reduction in symptoms" at 3 years, "back-to-back negative NFL readings" per Mantas; Centene already has draft guidance supporting coverage.

---

## Key Debates (Bull vs. Bear)

### A) GLP-1 Leadership: Lilly vs. Novo

- **Bull (LLY):** Ex-US injectable demand "flying off the shelves," $2B guide raise, Foundayo dose-down maintenance data, in-vivo CAR-T M&A diversifying away from incretins. (Fazeli, Biotech Hangout)
- **Bull (NVO):** Oral Wegovy is the largest GLP-1 launch in US history (1.3M scripts Q1), 80% of users treatment-naive, ~50% self-pay through Novocare expanding the funnel. (Dustar, Citeline)
- **Bear (NVO):** $149/mo self-pay price is ~1/10 of prior injectable, i.e. ASP destruction even at strong volumes; "no clear signs of NVO regaining overall market leadership." (Scrip)
- **Bear (LLY):** Foundayo launch trailing Novo's oral debut; reformulation/method-of-use generics in 2031+ on certain assets; sentiment "too long" coming into print per pre-earnings downgrades cited by Fazeli.

### B) FDA Regime Change: Net Positive or Destabilizing?

- **Bull:** Mantas (Logos LP) "quite bullish for gene therapy companies, cell therapy companies, gene editing companies, anything which is rare disease... Expensive drugs that can provide life-changing therapies." Sees Makary/Prasad-era as the lowest biologics approvals since 2018 despite a packed queue. (Intelligent Investing, May 13)
- **Bear:** Pink Sheet editor Ingerie warns "Temporary leadership is not good for the agency. It leads to uncertainty. It doesn't allow the FDA to move in any kind of direction or set any kind of priorities." Departures > hires at CDER/CBER for five straight quarters; FDA bonus cuts likely accelerating attrition. (Citeline, May 8)
- **Bear:** Gottlieb attributes recent FDA stumbles to weak political appointees displacing "strong career leadership in those medical product centers." (Squawk Pod, May 11)

### C) MFN / Drug Pricing

- **Bull (administration/markets near-term):** MFN deals already inked with 17 large drug-makers (incl. LLY, PFE, NVO, AMGN, MRK, JNJ, ABBV); TrumpRx.gov live since Feb; tariff-driven onshoring (LLY's incremental $4.5B Lebanon capex).
- **Bear (industry):** Watanabe (BIO Vice Chair) calls MFN "a very dangerous policy" that "will very quickly destroy the biopharmaceutical industry in the United States if it's implemented" and threatens capital formation in US biotech. (Citeline, May 12)

### D) Biotech Rotation: Commercial vs. Developmental

- **Bull (developmental):** Matteis: "this year, a number of [commercial] names have been laggards and it feels like it's been the year of developmental stage biotech." Eric Schmidt: "Everyone wants that open-ended five to 10 bagger upside associated with a readout pipeline event."
- **Bear (commercial):** NBIX and BMRN cited as "structurally cheap" but starved of investor attention; "Biomarin on an actual conservative valuation methodology is not expensive." Matteis sees an Alexion-style strategic take-out as the unlock.

### E) AI in Healthcare: Productive or Priced-In?

- **Bull:** Mantas: "AI just brings the cost of knowledge to zero... the number one beneficiary [is] areas where the cost of knowledge is an input, which is in biotech."
- **Bear:** "The only way you break Eroom's Law is changes in regulation. Not technological disruption." AI creates "a queue" but the regulatory bottleneck is unchanged.

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## Emerging Themes

- **In-vivo CAR-T as the next M&A front:** Lilly's Orno and Colonia ($3.25B upfront) acquisitions point to in-vivo CAR-T as the post-GLP-1 hedge in pharma BD. Watch ASH for Colonia myeloma data.
- **Direct-to-consumer / PBM disintermediation:** Lilly employer-direct and Novo's Novocare are creating a parallel low-list, high-volume self-pay channel; UNH's Optum Rx is responding with a "transparent" fee-based PBM model. Pricing model shift is a multi-year theme.
- **Hallmarks of a biotech bull:** Capital Group's Feingold and Logos LP's Mantas both flagging that generalist money is starting to look at biotech "with an AI biotech analyst in your pocket." Mantas: "the biggest biotech bubble that we've ever seen." Counter: still "very early days" per Matt Gline.
- **Neurofilament light chain (NfL) as a regulatory biomarker:** Clene's FDA signal that NfL can support ALS accelerated approval; uniQure showing serial-negative NfL reads in HD. Biomarker-led approvals are the gene-therapy unlock.
- **China-sourced assets:** UCB/Candid Therapeutics $2B upfront for T-cell engagers underscores the China BD channel, but Schimmer warns "the innovation there is almost too fast" and quality varies.
- **Healthcare as job-creation sector despite AI:** Yardeni and Sorkin both point to radiology/mammography as cases where AI expands rather than contracts demand for human professionals.

---

## Deals & M&A Tracker

| Acquirer / Investor | Target | Terms | Note |
| --- | --- | --- | --- |
| Angelini Pharma | Catalyst Pharmaceuticals | $4.1B | Rare disease consolidation |
| UCB | Candid Therapeutics | $2B upfront | T-cell engagers, China-sourced assets |
| Bayer | Perfused Therapeutics | ~$300M upfront + ~$2.5B biobucks | Ocular disease |
| Eli Lilly | Colonia | $3.25B upfront | In-vivo CAR-T (myeloma); data at ASH |
| Eli Lilly | Orno Therapeutics | n/d | In-vivo CAR-T, INI space |
| Eli Lilly | Ajax Therapeutics | up to $3.2B total | Type 2 JAK inhibitor, MPNs |
| Eli Lilly | Centessa | n/d | Closed earlier in 2026; ORX750 implications for Alkermes ALKS |
| GSK | Suzhou Siran Biotech (SA030 lic.) | up to $1B milestones + royalties | Siran's ALK7 siRNA, repurposed toward MASH |
| Blackstone (LP fund) | Life Sciences Fund VI close | $6.3B | Record close, capital availability for biotech |

LLY M&A YTD: ~6 deals, ~$14.5B aggregate upfront, "about half of the large pharma deals in terms of M&A" (Fazeli). Q1 2026 was a record quarter for biotech secondary offerings; 10 IPOs YTD raising ~$3.2B (Calera $719M obesity, Avalyn $300M IPF priced $18 trading ~$29, Seaport $255M CNS).

Speculative deal-talk: Merck evaluating a possible $30B acquisition of Revolution Medicines (RVMD) to backfill the Keytruda LOE.

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## Regulatory Watch

- **FDA Commissioner Makary resigned May 12** over disagreement on fruit-flavored e-cigarette authorization. Kyle Diamantas (top food regulator) named acting commissioner. President Trump confirmed via Truth Social. Permanent commissioner is the gating catalyst for gene/cell therapy approvals, with Mantas, Schmidt, and DeAngelis all flagging this as broadly bullish for the rare-disease and accelerated-approval ecosystem.
- **Vaping policy:** FDA announced enforcement discretion May 9 allowing all vaping/nicotine-pouch products under review to come to market immediately. Gottlieb: "you're going to see... dozens of new vaping products onto the market as a result of this policy."
- **COVID vaccine studies:** NYT (May 5) reports FDA has blocked publication of several studies supporting Covid and shingles vaccine safety, per HHS spokesperson; HHS Secretary Kennedy continuing a vaccine-safety inquiry behind the scenes (NYT, May 11).
- **MFN drug pricing:** 17 large drug-makers have signed MFN agreements through late April; April 2 EO placed tariffs on imported pharmaceuticals/APIs (administration projects $529B/10-yr savings).
- **IRA:** 2026 Part D redesign and ongoing "pill penalty" timing differentials between small-molecule and biologic exclusivity still re-shaping pipeline mix.
- **FDA staffing:** Departures > hires at CDER and CBER for 5 consecutive quarters; Makary hiring target of 3,000 scientists viewed skeptically by Pink Sheet, "strikingly similar to the amount of people that were targeted by the reduction in force last year."
- **CNPV program:** Commissioner's National Priority Voucher likely codified into PDUFA VIII (~2027); Sanofi withdrew teplizumab CNPV after FDA missed Apr 21 deadline.
- **Roche Elecsys pTau217 CE Mark (May 12):** blood-based diagnostic for amyloid pathology, co-developed with LLY; could unlock the diagnostic funnel for Kisunla/Leqembi.

---

## Week Ahead

**Near-term PDUFA dates (per web research):**

- **May 18:** AstraZeneca's Enhertu sBLA in neoadjuvant HER2+ early-stage breast cancer.
- **May 24:** Eisai/Biogen subcutaneous Leqembi autoinjector PDUFA, potential first at-home anti-amyloid initiation; commercial unlock.
- **May 29:** MannKind's Afrezza pediatric label expansion.
- **May 31:** Cingulate CTx-1301 ADHD stimulant.

**Other near-term catalysts (per podcast coverage):**

- Permanent FDA Commissioner and CBER head appointments (TBD), sector-wide and especially gene/cell therapy (QURE, BIIB, GILD, BMY, SRPT, RGNX).
- Summit Therapeutics Harmony-6 OS data as ASCO late-breaker (June), a competitive read for MRK Keytruda.
- LP(a) Phase 3 trial readout in 2026 (Novartis, Amgen), noted as a Capital Group conviction theme.
- Oral Wegovy international launches H2 2026.
- Lilly Colonia in-vivo CAR-T myeloma data at ASH 2026 (Dec).
- Q2 2026 commercial biotech earnings (July–Aug); watch Alnylam, Insmed, Argenix, Verona, NBIX, BMRN for the potential rotation back into commercial-stage names.
- PDUFA VIII reauthorization process building through 2027, CNPV codification.
- Continuing Hantavirus newsflow; MRNA, LLY, REGN potentially actionable on antibody therapeutics; Gottlieb skeptical on vaccine path.

---

## Sources

**Podcasts (May 8–15, 2026):**

- [Biotech Hangout, May 8 (Fazeli, Suvannavejh, Gline, Schmidt)](https://app.matterfact.com/podcasts/4da1687bc2cf38abcc8373edd56653574335ea4699b636f4ff15de246dd33b2d)
- [Biotech Hangout Ep. 182, May 8 (Matteis, Werber, Schimmer, DeAngelis)](https://app.matterfact.com/podcasts/a48b2949567295f75a6870d2b2fd674d2ed4877feff627b0d0039f04db80fff1)
- [Citeline Podcasts, May 11 (Big Pharma Q1 recap)](https://app.matterfact.com/podcasts/8be7690f0c478fa34ce4ceccabf8da74c4ef4fb4b46780388f6bc66c61a48834)
- [Citeline Podcasts, May 12 (Watanabe / BIO on MFN)](https://app.matterfact.com/podcasts/2297cc3e370f62c7bbc33bb822121042be4c9bc69b6742cf63533f915aee6045)
- [Citeline Podcasts, May 8 (Pink Sheet FDA leadership)](https://app.matterfact.com/podcasts/1176f98000e668e54d38c56f66c8deb8e7cf1f511760cdb4eea64d04e4a41808)
- [Squawk Pod, May 11 (Gottlieb, Sorkin, Yardeni)](https://app.matterfact.com/podcasts/df187a4ea1af1ef01b57cf774d168e790527d1d7bff40156a90979729f5d9892)
- [This Week in Intelligent Investing, May 13 (Mantas / Logos LP on QURE, FDA)](https://app.matterfact.com/podcasts/ff9662c1f9f5873c75382f6e104e894559ba3469e192260a4cff92ff7e33c832)
- [Capital Ideas, May 14 (Feingold / Capital Group)](https://app.matterfact.com/podcasts/3f2cd9dddf7230ad3740e7d1954176ffc2d0d61d47a07600678b636d34afc3cf)
- [The Rundown, May 11 (Hantavirus / MRNA)](https://app.matterfact.com/podcasts/2005230104892b34582858e448e38467469f9be3a304f495e4a58150ca3a17da)

**Selected news (UNH / LLY, May 5–14, 2026):**

- thefly (May 5): UnitedHealthcare cuts prior auth requirements by 30%
- thefly (May 6): Eli Lilly commits an additional $4.5B across Indiana manufacturing sites
- thefly (May 8): Eli Lilly PT raised to $1,235 from $1,183 at Guggenheim (Buy)
- thefly (May 11): Optum Rx announces 'transparent' pharmacy care model
- thefly (May 12): Roche receives CE Mark for Elecsys pTau217 (co-developed with LLY)
- thefly (May 12): FDA Commissioner Marty Makary resigns; Diamantas tapped as acting head
- thefly (May 12): Eli Lilly discloses SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN results at ECO
- thefly (May 13): UnitedHealth PT raised to $420 from $380 at BofA (Neutral)
- thefly (May 14): Eli Lilly / UNICEF USA $50M NCD collaboration (150th anniversary)
- NYT (May 5, May 11): FDA blocked publication of vaccine safety studies; Kennedy vaccine inquiry
- Web/sell-side context: XBI +~70% trailing 12mo; XLV YTD ~14.1% vs. SPX ~15%; UNH Q1 MLR 85.3% beat, EPS $7.23; 2027 MA final notice +2.48% vs. +0.09% proposed.

```request-access
variant: banner
heading: Run your own corpus.
description: matterfact is deployed with select institutional partners. Request access to run it on your own coverage.
buttonText: Request access
```